GW Pharmaceuticals now trades on the NASDAQ Global Market under the symbol GWPH

GW Pharmaceuticals is a biopharmaceutical company that is focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.

GW Pharmaceuticals Highlights -
GW Pharmaceuticals GWPH, commercialized the world’s first plant cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 20 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world.

GW Pharmaceuticals Website: http://www.gwpharm.com/default.aspx